PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Clinical trial NCT03927261 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03927261
- Sponsor
- Precigen, Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-20
- Primary completion
- 2024-08-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.